Identification
- Summary
Sulfacetamide is a sulfonamide used to treat inflammatory ocular conditions and acne vulgaris.
- Brand Names
- Avar, Blephamide, Cetamide, FML-S, Isopto Cetamide, Klaron, Ovace, Plexion, Sulf-10, Sumadan Wash, Sumaxin
- Generic Name
- Sulfacetamide
- DrugBank Accession Number
- DB00634
- Background
An anti-infective agent that is used topically to treat skin infections and orally for urinary tract infections.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Sulfacetamide (DB00634)
- Weight
- Average: 214.242
Monoisotopic: 214.041212886 - Chemical Formula
- C8H10N2O3S
- Synonyms
- Acetosulfamine
- N-((p-Aminophenyl)sulfonyl)acetamide
- N-(p-Aminobenzenesulfonyl)acetamide
- N-[(p-Aminophenyl)sulfonyl]acetamide
- N-Acetyl-4-aminobenzenesulfonamide
- N-Acetylsulfanilamide
- N-Sulfanilylacetamide
- N-Sulphanilylacetamide
- N'-acetylsulfanilamide
- N(1)-Acetyl-4-aminophenylsulfonamide
- N(1)-Acetylsulfanilamide
- p-Aminobenzenesulfonacetamide
- p-Aminobenzenesulfonoacetamide
- Sulfacetamid
- Sulfacetamida
- Sulfacétamide
- Sulfacetamide
- Sulfacetamidum
- Sulfanilazetamid
- Sulphacetamide
- Sulphacetamidum
- External IDs
- NSC-63871
Pharmacology
- Indication
For the treatment of bacterial vaginitis, keratitis, acute conjunctivitis, and blepharitis.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Acne vulgaris •••••••••••• Treatment of Conjunctivitis •••••••••••• •••••••••• Adjunct therapy in treatment of Trachoma •••••••••••• •••••••••• Treatment of Superficial ocular infection •••••••••••• •••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Sulfacetamide is a sulfonamide antibiotic with bacteriostatic actions and broad-spectrum activity against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus.
- Mechanism of action
Sulfacetamide is a competitive inhibitor of bacterial para-aminobenzoic acid (PABA), an essential component for bacterial growth (according to the Woods-Fildes theory). The inhibited reaction is necessary in these organisms for the synthesis of folic acid.
Target Actions Organism ADihydropteroate synthase inhibitorEscherichia coli (strain K12) ADihydropteroate synthase type-1 inhibitorEscherichia coli AFolic acid synthesis protein FOL1 inhibitorBaker's yeast - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
7-12.8 hours
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Oral LD50 Mouse : 16500 mg/kg. Side effects include moderate to severe erythema (redness) and moderate edema (raised kin), nausea, vomiting, headache, dizziness, and tiredness. Higher exposure causes unconsciousness.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAmbroxol The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Ambroxol. Articaine The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Articaine. Benzocaine The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Benzyl alcohol. Benzylpenicillin Sulfacetamide may decrease the excretion rate of Benzylpenicillin which could result in a higher serum level. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Sulfacetamide sodium 4NRT660KJQ 6209-17-2 IHCDKJZZFOUARO-UHFFFAOYSA-M - Product Images
- International/Other Brands
- Acetopt (Sigma Pharma) / Albucid (Allergan) / Anginamide (Medgenix) / Antebor (Kela) / Apisulfa (Amman) / Blef-10 (Allergan) / Bleph (Allergan) / Cetazin (Sigmapharm) / Oftasul (Dr. Collado) / Optal (Olan-Kemed) / Riacetamid (Riyadh Pharma) / Sulfacil (Farmak) / Sulphacalyre (Wallace) / Unisulf (Roster)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Balsulph Oph Liq 10.0% Solution / drops 100 mg / mL Ophthalmic Bausch & Lomb Inc 1989-12-31 1996-09-09 Canada 
Balsulph Oph Ont 10.0% Ointment 10 % Ophthalmic Bausch & Lomb Inc 1989-12-31 1997-09-12 Canada Bleph 10 Dps Solution / drops 10 % Ophthalmic Allergan 1964-12-31 2011-08-04 Canada Cetamide Ointment 100 mg/1g Ophthalmic Alcon 2007-01-08 Not applicable US 
Cetamide Ont 10% Ointment 10 % Ophthalmic Alcon, Inc. 1972-12-31 2009-04-24 Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Bleph-10 Solution / drops 100 mg/1mL Ophthalmic Allergan, Inc. 1971-06-01 2022-06-30 US Odan-sulfacetamide Solution 10 % Ophthalmic Odan Laboratories Ltd 1985-12-31 Not applicable Canada PMS-sulfacetamide Sod Oph Soln 30% Solution / drops 300 mg / mL Ophthalmic Pharmascience Inc 1991-12-31 2016-10-28 Canada PMS-sulfacetamide Sodium Liq 10% Liquid 10 % Ophthalmic Pharmascience Inc 1991-12-31 2016-10-28 Canada Sodium sulfacetamide Lotion 100 mg/1mL Topical Oceanside Pharmaceuticals 2015-12-18 Not applicable US 
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Blephamide Sulfacetamide sodium (100 mg/1mL) + Prednisolone acetate (2 mg/1mL) Suspension / drops Ophthalmic A-S Medication Solutions LLC 1961-10-01 Not applicable US Blephamide Sulfacetamide sodium (100 mg/1mL) + Prednisolone acetate (2 mg/1mL) Suspension / drops Ophthalmic Physicians Total Care, Inc. 1961-10-01 Not applicable US Blephamide Sulfacetamide sodium (10 %) + Prednisolone acetate (0.2 %) Solution / drops Ophthalmic Allergan 1989-12-31 2022-01-21 Canada Blephamide Sulfacetamide sodium (100 mg/1g) + Prednisolone acetate (2 mg/1g) Ointment Ophthalmic Allergan, Inc. 1987-01-01 Not applicable US Blephamide Sulfacetamide sodium (100 mg/1g) + Prednisolone acetate (2 mg/1g) Ointment Ophthalmic A-S Medication Solutions LLC 1987-01-01 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Avar Sulfacetamide sodium (95 mg/1g) + Octasulfur (50 mg/1g) Aerosol, foam Topical Mission Pharmacal Company 2010-07-15 2019-05-31 US Avar Sulfacetamide sodium (100 mg/1g) + Octasulfur (50 mg/1g) Emulsion Topical Mission Pharmacal Company 2011-09-15 Not applicable US Avar Cleansing Pads Sulfacetamide sodium (95 mg/1g) + Octasulfur (50 mg/1g) Cloth Topical Mission Pharmacal Company 2011-09-15 2019-11-30 US Avar Ls Sulfacetamide sodium (100 mg/1g) + Octasulfur (20 mg/1g) Emulsion Topical Mission Pharmacal Company 2011-09-15 Not applicable US Avar LS Sulfacetamide sodium (100 mg/1g) + Octasulfur (20 mg/1g) Aerosol, foam Topical Mission Pharmacal Company 2010-07-15 2019-09-30 US
Categories
- ATC Codes
- D10AF06 — Sulfacetamide
- D10AF — Antiinfectives for treatment of acne
- D10A — ANTI-ACNE PREPARATIONS FOR TOPICAL USE
- D10 — ANTI-ACNE PREPARATIONS
- D — DERMATOLOGICALS
- Drug Categories
- Amides
- Amines
- Aniline Compounds
- Anti-Acne Preparations
- Anti-Acne Preparations for Topical Use
- Anti-Bacterial Agents
- Anti-Infective Agents
- Anti-Infective Agents, Local
- Anti-Infective Agents, Urinary
- Antiinfectives for Treatment of Acne
- Dermatologicals
- Genito Urinary System and Sex Hormones
- Gynecological Antiinfectives and Antiseptics
- Ophthalmologicals
- Sensory Organs
- Sulfanilamides
- Sulfonamide Antibacterial
- Sulfonamides
- Sulfones
- Sulfur Compounds
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as aminobenzenesulfonamides. These are organic compounds containing a benzenesulfonamide moiety with an amine group attached to the benzene ring.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzenesulfonamides
- Direct Parent
- Aminobenzenesulfonamides
- Alternative Parents
- Benzenesulfonyl compounds / Aniline and substituted anilines / Organosulfonic acids and derivatives / Aminosulfonyl compounds / Acetamides / Amino acids and derivatives / Primary amines / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives show 1 more
- Substituents
- Acetamide / Amine / Amino acid or derivatives / Aminobenzenesulfonamide / Aminosulfonyl compound / Aniline or substituted anilines / Aromatic homomonocyclic compound / Benzenesulfonyl group / Carbonyl group / Carboxylic acid derivative show 12 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- substituted aniline, sulfonamide (CHEBI:63845)
- Affected organisms
- Enteric bacteria and other eubacteria
Chemical Identifiers
- UNII
- 4965G3J0F5
- CAS number
- 144-80-9
- InChI Key
- SKIVFJLNDNKQPD-UHFFFAOYSA-N
- InChI
- InChI=1S/C8H10N2O3S/c1-6(11)10-14(12,13)8-4-2-7(9)3-5-8/h2-5H,9H2,1H3,(H,10,11)
- IUPAC Name
- N-(4-aminobenzenesulfonyl)acetamide
- SMILES
- CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1
References
- General References
- Hull CA, Johnson SM: A double-blind comparative study of sodium sulfacetamide lotion 10% versus selenium sulfide lotion 2.5% in the treatment of pityriasis (tinea) versicolor. Cutis. 2004 Jun;73(6):425-9. [Article]
- Del Rosso JQ: Evaluating the role of topical therapies in the management of rosacea: focus on combination sodium sulfacetamide and sulfur formulations. Cutis. 2004 Jan;73(1 Suppl):29-33. [Article]
- Roth HW, Leimbeck R, Sonnenschein B, Anger CB, Weber S: [The effective antibacterial spectrum of sulfacetamide]. Klin Monbl Augenheilkd. 1992 Mar;200(3):182-6. [Article]
- External Links
- Human Metabolome Database
- HMDB0014772
- KEGG Drug
- D05947
- PubChem Compound
- 5320
- PubChem Substance
- 46504544
- ChemSpider
- 5129
- BindingDB
- 50316126
- 10169
- ChEBI
- 63845
- ChEMBL
- CHEMBL455
- ZINC
- ZINC000005179119
- Therapeutic Targets Database
- DAP001191
- PharmGKB
- PA451536
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Sulfacetamide
- FDA label
- Download (455 KB)
- MSDS
- Download (72.7 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Meibomian Gland Dysfunction (Disorder) 1 3 Completed Treatment Gastritis Associated With Helicobacter Pylori 1 0 Terminated Treatment Osteomyelitis 1
Pharmacoeconomics
- Manufacturers
- Sanofi aventis us llc
- Altana inc
- Perrigo co tennessee inc
- Taro pharmaceuticals usa inc
- Allergan pharmaceutical
- Alcon laboratories inc
- Schering corp sub schering plough corp
- Pharmafair inc
- Allergan
- Miza pharmaceuticals usa inc
- Akorn inc
- Sola barnes hind
- Novartis pharmaceuticals corp
- Optopics laboratories corp
- Alcon inc
- Alcon universal ltd
- Bausch and lomb pharmaceuticals inc
- Bausch and lomb inc
- Packagers
- A. Aarons Inc.
- Actavis Group
- Advanced Pharmaceutical Services Inc.
- Akorn Inc.
- Alcon Laboratories
- Allergan Inc.
- Amend
- A-S Medication Solutions LLC
- Bausch & Lomb Inc.
- Contract Pharm
- Coria Laboratories
- Dermik Labs
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- DPT Laboratories Ltd.
- E. Fougera and Co.
- Falcon Pharmaceuticals Ltd.
- Gorbec Pharmaceutical Services Inc.
- Groupe Parima Inc.
- H.J. Harkins Co. Inc.
- Harmony Laboratories Inc.
- Hawthorn Pharmaceuticals
- Innoviant Pharmacy Inc.
- Inyx Usa Ltd.
- Kaiser Foundation Hospital
- Kylemore Pharmaceuticals
- Major Pharmaceuticals
- Medical Ophthalmics
- Novartis AG
- Nycomed Inc.
- OMJ Pharmaceuticals
- Palmetto Pharmaceuticals Inc.
- Pegasus Laboratories Inc.
- Perrigo Co.
- Pharmaderm
- Pharmedix
- Physicians Total Care Inc.
- Prasco Labs
- Preferred Pharmaceuticals Inc.
- Rebel Distributors Corp.
- Redpharm Drug
- River's Edge Pharmaceuticals
- Sanofi-Aventis Inc.
- Sheffield Laboratories Div Faria Limited LLC
- Sonar Products Inc.
- Span Packaging Services LLC
- Spectrum Pharmaceuticals
- Stat Rx Usa
- Taro Pharmaceuticals USA
- Tiber Pharmaceuticals LLC
- United Research Laboratories Inc.
- Dosage Forms
Form Route Strength Solution / drops Ophthalmic Solution / drops Ophthalmic 100 mg / mL Solution / drops Ophthalmic 10 % Ointment Ophthalmic Suspension / drops Ophthalmic Ointment Ophthalmic 10 % Aerosol, foam Topical Emulsion Topical Ointment Ophthalmic; Topical Suspension Ophthalmic Cream Vaginal Solution / drops Ophthalmic 150 mg/1mL Lotion Topical 10 mg/1mL Solution Ophthalmic 10 % Aerosol, foam Topical 100 mg/1g Cream Topical 100 mg/1g Gel Topical 100 mg/1g Aerosol, foam Topical 98 mg/1g Lotion Topical 98 mg/1g Lotion / shampoo Topical 100 mg/1mL Shampoo Topical 100 mg/1mL Shampoo Topical 98 mg/1mL Soap Topical Suspension Topical Liquid Topical 100 mg/0.95mL Lotion Topical Lotion Topical 10 % Solution / drops Ophthalmic 300 mg / mL Gel Topical 100 mg/1mL Liquid Topical 100 mg/1g Liquid Topical 100 mg/1mL Lotion Topical 100 mg/1mL Solution Topical 100 mg/1g Swab Topical 100 mg/1mL Swab Topical Rinse Topical Gel Topical Kit Topical Solution Topical Solution Conjunctival; Ophthalmic 100 mg Solution Ophthalmic Ointment Ophthalmic Lotion Topical 100 mg/1g Ointment Ophthalmic 100 mg/1g Solution Ophthalmic 100 mg/1mL Solution / drops Ophthalmic 100 mg/1mL Solution / drops Ophthalmic 300 mg/1mL Suspension Topical 100 mg/1mL Solution Ophthalmic Solution / drops Ophthalmic Liquid Topical Cream Topical 10 % Solution Ophthalmic 100 mg Cloth Topical Cream Topical Liquid Ophthalmic 10 % Cloth; kit Topical Liquid Ophthalmic - Prices
Unit description Cost Unit Klaron 10% Lotion 118ml Bottle 155.38USD bottle Sulfacetamide-Sulfur Wash 10-4% Emulsion 473ml Bottle 138.03USD bottle Sulfacetamide Sodium-Sulfur 10-5% Lotion 25 gm Bottle 70.99USD bottle Sulfacetamide Sodium-Sulfur 10-5% Suspension 30 gm Tube 70.57USD tube Sulfacetamide Sodium-Sulfur 10-5% Lotion 30 gm Tube 63.38USD tube Sulfacetamide Sod-Sulfur Wash 10-5% Emulsion 170.1 gm Tube 55.94USD tube Bleph-10 10% Solution 5ml Bottle 22.7USD bottle Sulfacetamide Sodium 10% Solution 15ml Bottle 12.99USD bottle Bleph-10 10% eye drops 3.89USD ml Sulfacetamide powder 1.55USD g Klaron 10% lotion 1.29USD ml Sulfacetamide sod cryst powder 0.98USD g Sodium sulfacetamide 10% lot 0.94USD ml Sulfacetamide sod 10% top susp 0.8USD ml Ovace wash 10% liquid 0.44USD ml Re 10 wash 0.42USD ml Sulfacetamide 10% eye drops 0.34USD ml Sulfacetamide 10% ophth sol 0.34USD ml Sulfamide 10% eye drops 0.22USD ml Sodium sulfacetamide powder 0.1USD g DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 183 °C PhysProp water solubility 1.25E+004 mg/L (at 37 °C) YALKOWSKY,SH & DANNENFELSER,RM (1992) logP -0.96 HANSCH,C ET AL. (1995) logS -1.23 ADME Research, USCD - Predicted Properties
Property Value Source Water Solubility 4.21 mg/mL ALOGPS logP 0.15 ALOGPS logP -0.26 Chemaxon logS -1.7 ALOGPS pKa (Strongest Acidic) 4.3 Chemaxon pKa (Strongest Basic) 2.14 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 89.26 Å2 Chemaxon Rotatable Bond Count 1 Chemaxon Refractivity 52.48 m3·mol-1 Chemaxon Polarizability 20.49 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9912 Blood Brain Barrier + 0.9881 Caco-2 permeable - 0.5396 P-glycoprotein substrate Non-substrate 0.8806 P-glycoprotein inhibitor I Non-inhibitor 0.9743 P-glycoprotein inhibitor II Non-inhibitor 0.9449 Renal organic cation transporter Non-inhibitor 0.9484 CYP450 2C9 substrate Non-substrate 0.6975 CYP450 2D6 substrate Non-substrate 0.9058 CYP450 3A4 substrate Non-substrate 0.7775 CYP450 1A2 substrate Non-inhibitor 0.9609 CYP450 2C9 inhibitor Non-inhibitor 0.9595 CYP450 2D6 inhibitor Non-inhibitor 0.9312 CYP450 2C19 inhibitor Non-inhibitor 0.9546 CYP450 3A4 inhibitor Non-inhibitor 0.9552 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8371 Ames test Non AMES toxic 0.9279 Carcinogenicity Non-carcinogens 0.8623 Biodegradation Not ready biodegradable 0.9686 Rat acute toxicity 1.7849 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9919 hERG inhibition (predictor II) Non-inhibitor 0.9775
Spectra
- Mass Spec (NIST)
- Download (9.68 KB)
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0a4l-9810000000-3ed7ef5d2301b3bc79b4 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0a4i-0900000000-fbd2ce940d01e3db052d Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0002-0900000000-0967735897a615594942 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-00di-0910000000-6cc9a319069ad936958c Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-052f-9300000000-18e5af5377ffa0ab5fd2 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-004l-9200000000-cf381efa9ec15caf5d56 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-014l-9000000000-6d16e7b497ee5e26f9f7 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 151.7687814 predictedDarkChem Lite v0.1.0 [M-H]- 150.4512912 predictedDarkChem Lite v0.1.0 [M-H]- 151.7221814 predictedDarkChem Lite v0.1.0 [M-H]- 142.99619 predictedDeepCCS 1.0 (2019) [M+H]+ 152.5598814 predictedDarkChem Lite v0.1.0 [M+H]+ 153.6700814 predictedDarkChem Lite v0.1.0 [M+H]+ 152.9198814 predictedDarkChem Lite v0.1.0 [M+H]+ 145.39174 predictedDeepCCS 1.0 (2019) [M+Na]+ 151.9484814 predictedDarkChem Lite v0.1.0 [M+Na]+ 152.5882814 predictedDarkChem Lite v0.1.0 [M+Na]+ 151.30426 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Escherichia coli (strain K12)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Metal ion binding
- Specific Function
- Catalyzes the condensation of para-aminobenzoate (pABA) with 6-hydroxymethyl-7,8-dihydropterin diphosphate (DHPt-PP) to form 7,8-dihydropteroate (H2Pte), the immediate precursor of folate derivatives.
- Gene Name
- folP
- Uniprot ID
- P0AC13
- Uniprot Name
- Dihydropteroate synthase
- Molecular Weight
- 30614.855 Da
References
- Hevener KE, Zhao W, Ball DM, Babaoglu K, Qi J, White SW, Lee RE: Validation of molecular docking programs for virtual screening against dihydropteroate synthase. J Chem Inf Model. 2009 Feb;49(2):444-60. doi: 10.1021/ci800293n. [Article]
- BROWN GM: The biosynthesis of folic acid. II. Inhibition by sulfonamides. J Biol Chem. 1962 Feb;237:536-40. [Article]
- Patel OG, Mberu EK, Nzila AM, Macreadie IG: Sulfa drugs strike more than once. Trends Parasitol. 2004 Jan;20(1):1-3. [Article]
- Kind
- Protein
- Organism
- Escherichia coli
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Metal ion binding
- Specific Function
- Catalyzes the condensation of para-aminobenzoate (pABA) with 6-hydroxymethyl-7,8-dihydropterin diphosphate (DHPt-PP) to form 7,8-dihydropteroate (H2Pte), the immediate precursor of folate derivativ...
- Gene Name
- sulI
- Uniprot ID
- P0C002
- Uniprot Name
- Dihydropteroate synthase type-1
- Molecular Weight
- 30125.83 Da
References
- Patel OG, Mberu EK, Nzila AM, Macreadie IG: Sulfa drugs strike more than once. Trends Parasitol. 2004 Jan;20(1):1-3. [Article]
- Kind
- Protein
- Organism
- Baker's yeast
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Metal ion binding
- Specific Function
- Catalyzes three sequential steps of tetrahydrofolate biosynthesis.
- Gene Name
- FOL1
- Uniprot ID
- P53848
- Uniprot Name
- Folic acid synthesis protein FOL1
- Molecular Weight
- 93119.085 Da
References
- Patel OG, Mberu EK, Nzila AM, Macreadie IG: Sulfa drugs strike more than once. Trends Parasitol. 2004 Jan;20(1):1-3. [Article]
Drug created at June 13, 2005 13:24 / Updated at April 18, 2024 09:15